文献速递肾移植

HLA抗原脱敏策略助力高度致敏患者肾移植

Delisting of HLA antigens as a possible strategy to enable transplantation in highly sensitized patients with a cPRA ≥ 99.9.
PubMed 文献 · Kidney Int · 2025-01-01

高度致敏患者(尤其cPRA≥99.9%)获得移植机会极低。Cucchiari等开展前瞻性多中心研究,基于脱敏策略,初步结果表明该方法有潜力使这类终末期肾衰竭患者获得移植机会并提高生活质量。

要点

  • 脱敏策略可能使cPRA≥99.9%的高度致敏患者获得肾移植机会。
  • 该策略基于前瞻性多中心研究,初步结果支持其可行性。
  • 脱敏可能改善高度致敏终末期肾衰竭患者的生活质量。

核心结论

  • 脱敏策略有潜力使高度致敏的终末期肾衰竭患者获得移植机会并提高生活质量。

研究设计与样本

  • 前瞻性多中心研究,基于脱敏策略,研究对象为高度致敏患者(尤其cPRA≥99.9%)。

主要发现

  • 初步结果表明脱敏策略有潜力使高度致敏患者获得移植机会并提高生活质量。

临床怎么用

  • 对cPRA≥99.9%的高度致敏终末期肾衰竭患者,可考虑脱敏策略以增加移植可及性。

局限性

  • 结果为初步结果,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Highly sensitized patients (especially those with a calculated Panel Reactive Antibody ≥ 99.9%) have little to no chances of having access to transplantation. Recently, delisting of human leukocyte antigens has been proposed as a possible strategy to enable transplantation in such patients. In this article, Cucchiari et al. describe the results of a prospective multicenter study based on a delisting strategy. Preliminary results suggest that such an approach has the potential to enable access to transplantation and increase the quality of life of many highly sensitized patients in terminal kidney failure.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Cozzi E. Delisting of HLA antigens as a possible strategy to enable transplantation in highly sensitized patients with a cPRA ≥ 99.9. Kidney Int. 2025. PMID: 41110889. doi:10.1016/j.kint.2025.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。